John Davis is the Chief Scientific Officer of the Centre for Medicines Discovery (Oxford) and Director of Business Development for the Alzheimer’s Research UK – Drug Discovery Alliance. He has over 25 years of drug discovery expertise all the way from target identification to successful clinical proof of concept for a range of drug candidates in neurological disorders. Following postdoctoral training at the Ludwig Institute and the Salk Institute, he joined GlaxoSmithKline where he led a variety of non-clinical pharmacology research departments for pain and neurodegenerative diseases. In 2010, Professor Davis co-founded the spinout company Convergence Pharmaceuticals, which he later left to become Director of Discovery for Selcia, and CSO and cofounder of Cypralis before joining the University of Oxford.

Rafael Gómez Bombarelli is the Jeffrey Cheah Assistant Professor in Engineering in MIT’s Department of Materials Science and Engineering. His research is focused on accelerated discovery cycles and machine learning approaches for molecular design and optimisation. Professor Gómez Bombarelli’s work has been published in journals such as Science, Nature Chemistry, and Nature Materials, and has been featured in MIT Technology Review and Wall Street Journal. He earned a BS, MS and PhD in chemistry from the Universidad de Salamanca, followed by postdoctoral work at Heriot-Watt University, Harvard University and Kyulux North America before taking up his post at MIT.

Beth Hoffman PhD is a seasoned pharmaceutical and biotech executive. Beth is the CEO of San Diego-based Origami Therapeutics. During her distinguished career she has also served as Vice-President of Discovery Biology at Vertex Pharmaceuticals and held leadership positions at Amgen, Eli Lilly, and the NIH. Beth brings invaluable experience in drug
discovery and development, both from the R&D and business perspective.

Teodoro Laino leads the chemical computation and automated synthetic chemistry efforts at the Department of Cognitive Computing and Industry Solutions at the IBM Research Zurich Laboratory. He is interested in the application of machine learning to chemistry and materials science problems with the purpose of developing scalable, tech-enabled solutions to significantly improve chemical synthesis (e.g., IBM RXN for chemistry). A chemist by background, Dr Laino has a PhD in computational chemistry, after which he worked as a post-doctoral researcher at the University of Zurich developing algorithms for molecular dynamics simulation.

Sally brings a wealth of knowledge and experience to Arctoris. Her passion for people and development ensures we continue to invest in our ambitious talent and culture agenda. Sally has diverse experience in building high performance teams in high growth tech companies. She has been a member of the Chartered Institute for Personnel & Development for over 20 years and is a qualified occupational psychologist.

Steven is an internationally recognized leader in the biopharma space. He was the CEO of Decibel Therapeutics, CEO & Founder of Infinity Pharmaceuticals, Chief Business Officer of Millennium Pharmaceuticals, and also served as EVP of Corporate Development at Biogen. Steven advises the board on business strategy, the commercial and competitive landscape, and asset-based value-generation.